(NASDAQ: NBP) Novabridge Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Novabridge Biosciences's earnings in 2026 is -$75,483,000.On average, 3 Wall Street analysts forecast NBP's earnings for 2026 to be -$167,069,032, with the lowest NBP earnings forecast at -$245,774,501, and the highest NBP earnings forecast at -$84,041,433. On average, 3 Wall Street analysts forecast NBP's earnings for 2027 to be -$233,101,586, with the lowest NBP earnings forecast at -$277,149,969, and the highest NBP earnings forecast at -$187,692,533.
In 2028, NBP is forecast to generate -$255,992,872 in earnings, with the lowest earnings forecast at -$313,754,682 and the highest earnings forecast at -$196,096,676.